Cargando…

RNA Therapeutic Options to Manage Aberrant Signaling Pathways in Hepatocellular Carcinoma: Dream or Reality?

Despite the early promise of RNA therapeutics as a magic bullet to modulate aberrant signaling in cancer, this field remains a work-in-progress. Nevertheless, RNA therapeutics is now a reality for the treatment of viral diseases (COVID-19) and offers great promise for cancer. This review paper speci...

Descripción completa

Detalles Bibliográficos
Autores principales: Sartorius, Kurt, Antwi, Samuel O., Chuturgoon, Anil, Roberts, Lewis R., Kramvis, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115561/
https://www.ncbi.nlm.nih.gov/pubmed/35600358
http://dx.doi.org/10.3389/fonc.2022.891812
_version_ 1784709945583730688
author Sartorius, Kurt
Antwi, Samuel O.
Chuturgoon, Anil
Roberts, Lewis R.
Kramvis, Anna
author_facet Sartorius, Kurt
Antwi, Samuel O.
Chuturgoon, Anil
Roberts, Lewis R.
Kramvis, Anna
author_sort Sartorius, Kurt
collection PubMed
description Despite the early promise of RNA therapeutics as a magic bullet to modulate aberrant signaling in cancer, this field remains a work-in-progress. Nevertheless, RNA therapeutics is now a reality for the treatment of viral diseases (COVID-19) and offers great promise for cancer. This review paper specifically investigates RNAi as a therapeutic option for HCC and discusses a range of RNAi technology including anti-sense oligonucleotides (ASOs), Aptamers, small interfering RNA (siRNA), ribozymes, riboswitches and CRISPR/Cas9 technology. The use of these RNAi based interventions is specifically outlined in three primary strategies, namely, repressing angiogenesis, the suppression of cell proliferation and the promotion of apoptosis. We also discuss some of the inherent chemical and delivery problems, as well as targeting issues and immunogenic reaction to RNAi interventions.
format Online
Article
Text
id pubmed-9115561
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91155612022-05-19 RNA Therapeutic Options to Manage Aberrant Signaling Pathways in Hepatocellular Carcinoma: Dream or Reality? Sartorius, Kurt Antwi, Samuel O. Chuturgoon, Anil Roberts, Lewis R. Kramvis, Anna Front Oncol Oncology Despite the early promise of RNA therapeutics as a magic bullet to modulate aberrant signaling in cancer, this field remains a work-in-progress. Nevertheless, RNA therapeutics is now a reality for the treatment of viral diseases (COVID-19) and offers great promise for cancer. This review paper specifically investigates RNAi as a therapeutic option for HCC and discusses a range of RNAi technology including anti-sense oligonucleotides (ASOs), Aptamers, small interfering RNA (siRNA), ribozymes, riboswitches and CRISPR/Cas9 technology. The use of these RNAi based interventions is specifically outlined in three primary strategies, namely, repressing angiogenesis, the suppression of cell proliferation and the promotion of apoptosis. We also discuss some of the inherent chemical and delivery problems, as well as targeting issues and immunogenic reaction to RNAi interventions. Frontiers Media S.A. 2022-05-04 /pmc/articles/PMC9115561/ /pubmed/35600358 http://dx.doi.org/10.3389/fonc.2022.891812 Text en Copyright © 2022 Sartorius, Antwi, Chuturgoon, Roberts and Kramvis https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Sartorius, Kurt
Antwi, Samuel O.
Chuturgoon, Anil
Roberts, Lewis R.
Kramvis, Anna
RNA Therapeutic Options to Manage Aberrant Signaling Pathways in Hepatocellular Carcinoma: Dream or Reality?
title RNA Therapeutic Options to Manage Aberrant Signaling Pathways in Hepatocellular Carcinoma: Dream or Reality?
title_full RNA Therapeutic Options to Manage Aberrant Signaling Pathways in Hepatocellular Carcinoma: Dream or Reality?
title_fullStr RNA Therapeutic Options to Manage Aberrant Signaling Pathways in Hepatocellular Carcinoma: Dream or Reality?
title_full_unstemmed RNA Therapeutic Options to Manage Aberrant Signaling Pathways in Hepatocellular Carcinoma: Dream or Reality?
title_short RNA Therapeutic Options to Manage Aberrant Signaling Pathways in Hepatocellular Carcinoma: Dream or Reality?
title_sort rna therapeutic options to manage aberrant signaling pathways in hepatocellular carcinoma: dream or reality?
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9115561/
https://www.ncbi.nlm.nih.gov/pubmed/35600358
http://dx.doi.org/10.3389/fonc.2022.891812
work_keys_str_mv AT sartoriuskurt rnatherapeuticoptionstomanageaberrantsignalingpathwaysinhepatocellularcarcinomadreamorreality
AT antwisamuelo rnatherapeuticoptionstomanageaberrantsignalingpathwaysinhepatocellularcarcinomadreamorreality
AT chuturgoonanil rnatherapeuticoptionstomanageaberrantsignalingpathwaysinhepatocellularcarcinomadreamorreality
AT robertslewisr rnatherapeuticoptionstomanageaberrantsignalingpathwaysinhepatocellularcarcinomadreamorreality
AT kramvisanna rnatherapeuticoptionstomanageaberrantsignalingpathwaysinhepatocellularcarcinomadreamorreality